John Bradshaw

Designs and develops new medicines targeting G protein-coupled receptors

Develops glucose monitoring devices

Engages in the development of new medicines based on antibody fragment technology

Designs and develops respiratory diagnostic and monitoring equipment

Develops novel glucosinolate based products for the prevention and treatment of human disease

Manufactures high performance solar cells

Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye

Develops, manufactures and commercializes medical device technologies

Engages in clinical development of therapeutics

Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements.

Operates as a biotechnology that develops new medicines

Provides accounting, auditing and bookkeeping services

Operates as a healthcare executives, thought leaders and industry professional platform

Develops CROMA electrosurgical platform

Syncona aims to build a sustainable, diverse portfolio of 15-20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which they are seeking to deliver strong risk-adjusted returns for shareholders. The firm takes a long-term view, underpinned by a strategic capital base which enables them to maintain significant ownership positions in their companies and provides them with control and flexibility over the management of their portfolio.

Provides investment services

Science Creates Ventures invests in companies located in the United Kingdom. The firm focuses on the technology sector. It provides capital for seed and early stage capital requirements.